DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $12.00.

Several equities analysts have commented on DMAC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th.

Institutional Investors Weigh In On DiaMedica Therapeutics

Large investors have recently modified their holdings of the business. AWM Investment Company Inc. acquired a new position in shares of DiaMedica Therapeutics during the 2nd quarter worth $253,000. Bank of New York Mellon Corp bought a new position in DiaMedica Therapeutics in the second quarter valued at about $829,000. Bank of America Corp DE grew its position in DiaMedica Therapeutics by 62.5% in the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the last quarter. Renaissance Technologies LLC acquired a new position in DiaMedica Therapeutics during the first quarter worth about $356,000. Finally, Sei Investments Co. raised its stake in DiaMedica Therapeutics by 100.0% during the first quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after acquiring an additional 55,660 shares in the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC opened at $6.74 on Wednesday. DiaMedica Therapeutics has a 52 week low of $5.14 and a 52 week high of $10.42. The stock has a market capitalization of $363.49 million, a P/E ratio of -9.36 and a beta of 1.01. The stock’s fifty day moving average is $6.85 and its 200 day moving average is $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Equities research analysts forecast that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical?stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein?kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.